{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of events for median, upper limit not calculable","groupId":"OG000","lowerLimit":"11.01","upperLimit":"NA","value":"NA"},{"comment":"upper limit not calculable","groupId":"OG001","lowerLimit":"4.14","upperLimit":"NA","value":"11.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Refractory Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) that has recurred during or less than 6 months after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Refractory Subgroup"}],"paramType":"MEDIAN","populationDescription":"Platinum Refractory Responders","reportingStatus":"POSTED","timeFrame":"Approximately up to 30 months (from FPFV to Data base lock)","title":"Duration of Response (DOR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup","type":"PRIMARY","unitOfMeasure":"Months"}